|
会议详情 |
|
2026-06-04 08:30 至 2026-06-05 17:00
300人
优惠信息：
发票类型：增值税普通发票
参会凭证：邮件/短信发送参会通知
The Global Biotech & Pharma Patent (China) Summit 2026 will bring together leading pharmaceutical companies, biotech firms, research institutions, law firms, intellectual property agencies, and industry experts from around the world. Centered on the core theme of "Focus on APAC Global Vision，Guided by Insight, Innovation Without Borders," and the summit will delve into patent strategies for cutting-edge technologies, global patent deployment and management, cross-border licensing and collaboration, as well as the latest trends in policies and ethics.
We are in an era of global health revolution driven by biotechnological innovation. From gene editing to AI-driven drug discovery, disruptive technologies are redefining pharmaceutical R&D. In this process, intellectual property—particularly patents—serves not only as a legal shield but also as a core strategic asset determining the value of technology transfer and global collaboration.China has emerged as an indispensable presence in this landscape. With substantial R&D investment and a maturing ecosystem, it has transitioned from a "fast follower" to a "parallel leader," contributing original achievements across multiple fields while deepening global collaboration.
However, the global patent landscape is increasingly complex, with regional differences in examination, cross-border enforcement challenges, and new models like open-source licensing. These demand more sophisticated IP strategies. Key questions now are: How to build a patent system combining international vision with local expertise? How to accelerate innovation through strategic IP management? The answers will determine the biopharmaceutical industry's success in the coming decade. These points are precisely part of the original intent behind hosting this summit and part of the key topics to be discussed with relevant professionals.
Join us on Jun 4th-5th! Register now to reserve your place at this exclusive event.
Day 1 Morning：The integration and challenges of regulatory science and the patent system |
ü Latest Practices and Future Prospects of Drug Data Protection and Market Exclusivity Systems ü How to Optimize Application Strategies and Quality Management of Biopharmaceutical Patents under the Fast-Track Patent Examination System ü Patent Challenges in the ADC/Bispecific Antibody 2.0 Era ü A New Balance Under Global Competition and Cooperation: Challenges, Evolution, and Multinational Corporate Strategies of Biopharmaceutical Patent Linkage Systems |
Day 1 Afternoon：Maximizing Patent Value and New Commercialization Models |
ü Biosimilar Patent Challenge Strategies and Patent Cliff Management ü Patent Due Diligence and Investment Risks ü Trade Secrets vs. Patent Trademarks: Biopharmaceutical Innovation Protection Strategies in High-Risk Litigation ü Maximizing Innovation Value Using a Composite Intellectual Property Strategy (Patent + Data Protection) ü Intellectual Property Risks and Management in the Context of Supply Chain Restructuring and Digital Therapy Compliance |
Day 2 Morning：Global Perspective on Biopharmaceutical R&D and Patent Strategies and Competition |
ü How to Develop Differentiated Claim Strategies to Cope with Strict Inventiveness/Obviousness Examinations in Various Countries ü Patent Issues and Intellectual Property Risk Prevention in Cross-Border Biopharmaceutical Collaboration ü Patent Layout and Cross-Border Expansion Strategies for Pharmaceutical Companies ü Patent Issues in Cross-Border Biopharmaceutical Collaboration and Strategies for Protecting Pharmaceutical Intellectual Property |
Day 2 Afternoon：Opportunities and Legal Challenges of AI in Biotechnology and Pharmaceutical Intellectual Property |
ü Patent Challenges and Strategies for AI-Driven Drug Discovery, Gene Editing, and Cell and Gene Therapy ü Patent Eligibility and Data Protection in AI-Driven Drug Development ü Balance and Development of Innovative and Generic Drugs under the Drug Patent Linkage System ü Deep Integration of AI in Drug Development and Intellectual Property Protection Strategies |
Summit Presents:
300+ Participants
100+ Biotech & Pharma Companies
20+ Authoritative Speakers
10 Hours+ Networking
10+ Exhibition Booth
Partial inviting Companies & Institutions :
CNIPA | EUIPO | WIPO |
PhIRDA | Eli Lilly and Company | Novo Nordisk |
Johnson & Johnson | AbbVie | Merck Sharp & Dohme |
Roche | AstraZeneca | Novartis |
Pfizer | Amgen | Sanofi |
GileadSciences | Bristol-Myers Squibb | Vertex Pharmaceuticals |
Regeneron Pharmaceuticals | Novo Nordisk | Chugai Pharmaceutical |
GSK | Merck KGaA | Sun Pharmaceutical |
CVS Health | Daiichi Sankyō | LONZA |
Takeda Pharmaceutical | Hengrui Pharmaceuticals | UCB |
Argenx | Alnylam Pharmaceuticals Inc | Celltrion |
Otsuka Holdings | Galderma Group | TEVA |
WuXi AppTec | West Pharmaceutical | BeiGene |
Biogen Inc | LabCorp | Bayer |
Divis Laboratories | Sandoz | ICON |
Astellas Pharma | Moderna | Baxter |
Neurocrine Biosciences | Cipla Ltd., | Viatris |
Hansoh Pharm | Dr. Reddy's | Lupin Limited |
Servier | Incyte, Corp | Genmab |
Eisai | Luoxin Pharmaceutical Group | CSPC Pharma |
Tide Pharmaceutical | BRILLIANT PHARMACEUTICAL | Innovent Biologics |
Bio-Thera Solutions | Salubris Pharmaceuticals | Haiscom pharmaceutical |
Easton Biopharmaceuticals | Hua Medicine | Genscript Corporation |
TransThera Biosciences | CHIPSCREEN BIOSCIENCES | Humanwell Pharmaceutical |
Fosun Kite Biotechnology | Hybio Pharmaceutical | Allist Pharmaceuticals |
Xiangxue Life Sciences | Humanwell Healthcare | XuanZhu Pharma |
Staidson | Shineway Pharmaceutical | Kanghong Pharmaceutical |
I-Mab Biopharma | CRDC | New Era Pharmaceutical |
Ascentage Pharma | ARSUAMOON | Jiangxi Jemincare Group |
Yangzijiang Pharmaceutical | LintonPharm Co., Ltd. | Grand Pharmaceutical |
Qilu Pharmaceutical | Shanghai Pharmaceuticals | Kelun Pharmaceutical |
Buchang Pharmaceuticals | Livzon Pharmaceutical | SunshineLake |
Huahai Pharmaceutical | Conba Pharmaceutical | 3SBio Inc. |
Jiuzhou Pharmaceutical | Hisun Pharmaceutical | Simcere Pharmaceutical |
Beijing Intellectual Property Court | Shanghai Technology Exchange | Nhwa Pharmaceutical |
Tongyuankang Pharmaceutical | Kangma Biotechnology | Rege Biotech |
Zhejiang BaiChengPharmaceutical | Tongji University | HitGen Inc. |
Impact Therapeutics | Hutchison China MediTech | CR Double Crane |
Sinocelltech | Gendicine Biopharmaceutical | Shenyang Xingqi Pharmaceutical |
Impact Therapeutics | Asieris Pharmaceuticals | Metsera |
LaNova Medicines | Innolake Biopharm | Chengdu Guowei Biological |
Ribo Life Science | Johnson & Johnson MedTech | Adlai Nortye |
Kejun Pharmaceutical | Beijing Wuhe Boao Pharmaceutical | Youjia (Hangzhou) Biotechnology |
Lyvgen Biopharma | Mabwell (Shanghai) Bioscience | IASO Bio |
TOT Biopharm | Suzhou Gelanke Pharmaceutical | BioNTech |
SanegeneBio | Medical Academy of Sciences & Research | Kangbaida (Sichuan) Biological |
Shanghai Luoqi Biotechnology | Yuekang Kechuang Pharmaceutical | SunshineLake |
Kelun-Bota Biotech | China Biologic Products | Junhemeng Biotech |
Xiamen Amoytop Biotech | Yuansong Biotechnology | WuXi Biologics |
J Xinnian Pharmaceutical | Shanghai Yunsheng Yanxin Biotech | Simcere Pharmaceutical |
上海瞻仕商务咨询有限公司是一家专注于金融，保险，生物，医药，互联网，能源化工等领域的峰会策划咨询机构。核心团队由十年以上会议行业人士组成，致力于为行业精英提供学习和交流平台，为客户提供行业鲜活的话题，解读热点的政策法规，分享前沿的创新技术。始终坚持“客户为本，合作发展，多元共赢”的经营理念，锐意进取，全力打造会议行业标杆。
| 票种名称 | 价格 | 原价 | 票价说明 |
| 早鸟票 | ¥3800 | ¥3800 | 参会，午餐，茶歇，活动资料 |
相关会议
2026-03-20汕头
2026-04-09上海
商务会议
会议嘉宾
会议主办方
会议场地
会议PPT
APP参会
订单查询
开通会员
